IRVINE, Calif.--(BUSINESS WIRE)--CG Oncology, Inc., a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer, announced today it has triggered the first development milestone payment under its licensing agreement with Kissei Pharmaceutical Co., Ltd. for its oncology immunotherapy CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China.
ST. GALLEN, Switzerland--(BUSINESS WIRE)--Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that Japan’s Ministry of Health and Labor Welfare (MHLW) has granted its partner, Kissei Pharmaceutical Co., Ltd., marketing authorization approval for TAVNEOS® for the treatment of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the two main types of ANCA-associated vasculitis, a rare and severe autoimmune renal disease with high unmet medical need.
Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto, Nagano; Chairman and CEO: Mutsuo Kanzawa) announced that it has entered into a license agreement with Bio Genuine (Head Office: People's Republic of China, CEO: Baohua Ji) to license development and commercialization rights in China for the GnRH antagonist linzagolix that was discovered by Kissei.
Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals
Eli Lilly has a message for the U.S. Supreme Court: We aren’t going to take a $20 million patent loss for Cialis sitting down. Now, Lilly can count on a couple of friends ready to join the fight—and it's a fight that the rest of pharma might want to watch.
Imbruvica (ibrutinib): Pharmacyclics, Janssen Biotech vs. Hetero Labs
Velcade (Bortezomib): Millennium Pharmaceuticals vs Hetero Labs Limited